- Home
- CWK vs RCUS Comparison
CWK vs RCUS Comparison
Compare CWK & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CWK | RCUS |
|---|---|---|
| Founded | 1784 | 2015 |
| Country | United States | United States |
| Employees | 53000 | 601 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.9B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CWK | RCUS |
|---|---|---|
| Price | $12.93 | $23.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $17.64 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 1.5M | 891.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,288,200,000.00 | $247,000,000.00 |
| Revenue This Year | $6.87 | N/A |
| Revenue Next Year | $5.98 | $45.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.91 | N/A |
| 52 Week Low | $9.68 | $7.92 |
| 52 Week High | $17.40 | $28.72 |
Technical Indicators
Market Signals| Indicator | CWK | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 45.59 |
| Support Level | $11.73 | $20.20 |
| Resistance Level | $14.57 | $24.33 |
| Average True Range (ATR) | 0.60 | 1.15 |
| MACD | -0.12 | -0.29 |
| Stochastic Oscillator | 31.49 | 21.52 |
Price Performance
Historical ComparisonAbout CWK Cushman & Wakefield plc
Cushman & Wakefield is one of the largest commercial real estate services firms in the world and is headquartered in Chicago. The firm provides a broad suite of real estate-related services to owners, tenants, and investors. These include brokerage services for leasing and capital markets sales as well as advisory services such as valuation, project management, and facilities management.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.